- Report
- May 2024
- 183 Pages
Global
From €3237EUR$3,374USD£2,781GBP
€3596EUR$3,749USD£3,090GBP
- Report
- September 2023
- 180 Pages
Global
From €5708EUR$5,950USD£4,903GBP
- Report
- November 2023
- 146 Pages
Global
From €2397EUR$2,499USD£2,059GBP
- Report
- December 2022
- 115 Pages
Global
From €4701EUR$4,900USD£4,038GBP
- Report
- August 2022
- 110 Pages
Global
From €4557EUR$4,750USD£3,914GBP
- Report
- August 2019
- 30 Pages
China
From €2110EUR$2,200USD£1,813GBP
- Report
- March 2020
- 40 Pages
Saudi Arabia
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
Russia
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
India
From €2489EUR$2,595USD£2,139GBP
- Report
- February 2020
- 100 Pages
Global
From €4600EUR$4,795USD£3,952GBP
- Report
- January 2021
- 140 Pages
China, Global
From €3000EUR$3,350USD£2,667GBP
- Drug Pipelines
- June 2021
- 44 Pages
Global
From €1919EUR$2,000USD£1,648GBP
- Report
- March 2020
- 40 Pages
United States
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
South Korea
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
Japan
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
Ireland
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
Germany
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
France
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
China
From €2489EUR$2,595USD£2,139GBP
- Report
- March 2020
- 40 Pages
Brazil
From €2489EUR$2,595USD£2,139GBP
Urokinase is a type of cardiovascular drug used to treat a variety of conditions, including pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. It is a thrombolytic agent, meaning it works by breaking down blood clots and restoring blood flow to the affected area. Urokinase is administered intravenously and is typically used in combination with other medications. It is also used to prevent the formation of new blood clots.
Urokinase is a widely used drug in the cardiovascular market, with a variety of manufacturers offering it in different forms. It is available in both generic and branded versions, with the latter being more expensive. The drug is also available in different concentrations, depending on the patient's needs.
Some of the companies in the Urokinase market include Pfizer, Sanofi, Merck, and Bristol-Myers Squibb. Show Less Read more